Relaxin remodels fibrotic healing following myocardial infarction
Open Access
- 1 May 2011
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 91 (5), 675-690
- https://doi.org/10.1038/labinvest.2010.198
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Myocardial oxidative stress contributes to transgenic β2‐adrenoceptor activation‐induced cardiomyopathy and heart failureBritish Journal of Pharmacology, 2011
- Relaxin inhibits renal myofibroblast differentiationviaRXFP1, the nitric oxide pathway, and Smad2The FASEB Journal, 2008
- Immunogold labeling study of the distribution of GLUT-1 and GLUT-4 in cardiac tissue following stimulation by insulin or ischemiaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- ‘Relaxin’ the stiffened heart and arteries: The therapeutic potential for relaxin in the treatment of cardiovascular diseasePharmacology & Therapeutics, 2006
- Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmiaImmunology, 2006
- Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive RatsHypertension, 2005
- Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine modelThe FASEB Journal, 2005
- Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissueBiochemical and Biophysical Research Communications, 2004
- Relaxin deficiency in mice is associated with an age‐related progression of pulmonary fibrosisThe FASEB Journal, 2002
- Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivoGut, 2001